Shengnuo Biotechnologytechnology Science and Technology Innovation Board is listed to strengthen the two-way competitive advantage of peptide innovative drug pharmaceutical research services and independent peptide drug products

On June 3, 2021, Shengnuo Biotechnologytechnology Co., Ltd. officially listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange, stock abbreviation: Shengnuo Biotechnology, stock code: 688117. The total number of new shares issued this time is 20 million shares, and the issue price is RMB 17.90 per share. The sponsor (lead underwriter) is Minsheng Securities Co., Ltd.

On June 3, 2021, Shengnuo Biotechnology Co., Ltd. officially listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange, stock abbreviation: Shengnuo Biotechnology, stock code: 688117. The total number of new shares issued this time is 20 million shares, and the issue price is RMB 17.90 per share. The sponsor (lead underwriter) is Minsheng Securities Co., Ltd.

Shengnuo Biotechnology is a high-tech enterprise with core peptide synthesis and modification technologies. Its main business is independent research and development, production and sales of peptide APIs and preparation products, and provides pharmaceutical research services and peptide products for innovative peptide drugs at home and abroad. Customized production services and technology transfer services for peptide drug production. In addition, Shengnuo Biotechnology also provides small-molecule chemical drug levosimendan preparations on behalf of processing and levosimendan bulk drug production, export sales business.

In this listing, Shengnuo Biotechnology has raised 349 million yuan of funds, which will be used for the annual production of 395 kilograms of peptide API production line projects, preparation industrialization technology transformation projects, and engineering technology center upgrade projects.

Shengnuo Biotechnologytech stated that after the completion of the project, the company’s production scale, product structure, and research and development capabilities will be significantly improved. The construction of each project in the company’s future strategic layout not only captures the future development trend of the peptide drug industry, is conducive to the company’s new product research and development and industrialization, but also helps the company expand its production scale, alleviate the company’s insufficient production capacity, and consolidate the company’s peptide innovation The competitive advantage of “pharmaceutical research services + independent peptide drug products”.

Product lines support steady growth in revenue

Since its establishment, Shengnuo Biotechnology has been continuously researching and developing technologies for the large-scale production of peptide drugs. At present, it has successfully developed a number of popular API varieties in domestic and foreign markets. At the same time, it provides pharmaceutical research services for peptide innovative drugs and customized production services for peptide products. , The number of peptide APIs and the number of foreign service projects are among the best in China.

Relying on the core technology advantages of peptide synthesis and modification, Shengnuo Biotechnology has gained a high reputation and recognition in the field of peptide drug R&D and production. At the same time, because the pharmaceutical industry is a strategic industry strongly supported by the country, Shengnuo Biotechnology has been supporting the development of the industry in recent years.

The policy is to continue to explore the peptide drug market and achieve breakthroughs in research and development to maintain steady growth in corporate revenue. According to the financial report, in 2021 Q1, Shengnuo Biotechnologytechnology realized operating income of 93,280,200 yuan, an increase of 30.47% over the same period last year; realized net profit attributable to shareholders of the parent company of 11,654,400 yuan, a year-on-year increase of 37.12%; realized deduction of non-recurring profits The net profit attributable to shareholders of the parent company was 11.825 million yuan, a year-on-year increase of 44.73%.

Based on the core technology in the market

Shengnuo Biotechnology’s revenue growth is due to the fact that the company’s main business peptide APIs and preparation products have a large market capacity and strong competitiveness at home and abroad. Because peptide APIs are unique in clinical application and production and preparation In recent years, the growth rate of the peptide drug market is about twice that of the overall growth rate of the global drug market. At the same time, the Asian region is the fastest-growing region in the peptide drug market.

Its large patient population, growing medical expenditures and attention to innovative treatments will promote the growth of the peptide therapy market in the Asia-Pacific region.

Currently in the domestic market, Shengnuo Biotechnology has obtained 7 varieties of domestic production approvals, of which enfuvirtide and carbetocin are the first domestic imitation varieties; in foreign markets, the company’s liraglutide and other 8 varieties Acquired the U.S. DMF activation record, which can be cited and declared by preparation manufacturers. At the same time, the company is continuing to expand the product market.

With the expansion of the domestic and foreign peptide drug market in recent years, the operating income of Shengnuo Biotechnology has increased from 277,973,500 in 2018. The net profit increased from RMB 29,861,300 in 2018 to RMB 5,999.78 in 2020, and the net sales margin was 10.74%, 14.73%, and 15.84%, respectively.

R&D and industrial chain platforms help product promotion

In terms of research and development, by virtue of its core technology advantages in peptide synthesis and modification, Shengnuo Biotechnology has gained high popularity and recognition in the field of peptide drug R&D and production.

It has provided more than 30 pharmaceutical research projects for many well-known new drug R&D companies and scientific research institutions. service. As of March this year, Shengnuo Biotechnology has mastered the large-scale production technology of 15 varieties of APIs, of which 7 varieties have obtained domestic production approvals, 8 varieties have obtained the US DMF registration (active state), and 8 peptide preparations have been extended. The variety has obtained 12 production approvals in China, and the products cover areas where peptide drugs play an important role in immune system diseases, tumors, cardiovascular, chronic hepatitis B, diabetes and obstetric diseases.

While continuing to develop new products and open up product application areas, Shengnuo Biotechnology has also built a full-process R&D pipeline and a full-industry chain platform for peptide APIs and preparations, which can provide innovative peptide drugs and generic drugs from process route design to Pharmaceutical research services such as pilot trials, pilot trials, verification production and quality control, as well as the entire chain of customized production services for APIs and preparation products required for drug R&D and commercial production, covering everything from drug discovery, preclinical research, to clinical trials and Complete drug development cycle for marketing.

Shengnuo Biotechnologytech stated in the prospectus that in the follow-up development,

the company will seize the development opportunities of the rapid growth of the peptide generic drug market, continue to deepen the peptide drug market, and continue to improve process technology, R&D strength, marketing management, channel construction and Comprehensive management capabilities, improve overall competitiveness and profitability, grasp the development trend of the global pharmaceutical industry, and actively integrate into the pharmaceutical industry chain at home and abroad with the help of pharmaceutical research services for peptide innovative drugs, customized production services for peptide products, and peptide API products.

At the same time, it will extend the development of more varieties of peptide preparations, and further increase the promotion of preparations and the level of promotion management. At the same time, Shengnuo Biotechnology will actively deploy the peptide innovative drug business field through cooperative research and development, and consolidate the company’s competitive position in the industry.